For the roughly 10% of women with endometriosis whose disease invades the bowel wall deeply enough to require colectomy, choosing the right surgical platform could dramatically alter their reproductive future and decade-long pain trajectory. That choice — robotic versus conventional laparoscopic — has lacked robust comparative data, leaving surgeons and patients navigating uncertainty in one of gynecologic surgery's most technically demanding procedures.
This retrospective propensity-matched cohort study drew from the TriNetX US Collaborative Network, spanning 72 healthcare organizations. After excluding patients with prior hysterectomy, malignancy, inflammatory bowel disease, and open conversion, 487 women per arm were matched on baseline characteristics and followed for up to five years. Robotic colectomy was associated with a relative risk of recurrence of just 0.21 at three years — meaning disease came back in 4.3% of the robotic group versus 20.1% in the laparoscopic group. Pregnancy achievement roughly doubled (7.2% vs 2.9% at three years), and long-term opioid use was meaningfully lower in the robotic cohort (68.4% vs 89.3%). These signals persisted and remained directionally consistent at five years, with emergency readmissions also lower in the robotic group (26.7% vs 35.1%). Notably, pelvic pain, dysmenorrhea, urinary dysfunction, and incontinence rates were statistically comparable between approaches.
Several limitations temper enthusiasm. This is a retrospective, claims-derived analysis, not a randomized trial, so unmeasured confounding — particularly surgeon experience and institutional volume, both strongly associated with robotic platform adoption — cannot be excluded. The recurrence differential is striking and warrants scrutiny: a roughly fourfold reduction is unusually large for a platform comparison and may partly reflect case-selection bias even after propensity matching. Pregnancy rates, while statistically significant, remain low in absolute terms for both arms, limiting clinical extrapolation. The study cannot capture completeness of excision, a critical driver of recurrence in deep infiltrative disease. Still, as an hypothesis-generating signal across a broad US hospital network, these findings make a compelling case for a prospective randomized trial comparing surgical platforms in bowel endometriosis — a disease where current treatment leaves most patients cycling through repeated interventions.